PATENT CLAIM ANALYSIS

Application Number: 16060559
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "184000"]

Abstract:
The present invention relates to novel monomaleimide-functionalized platinum compounds of formula (I), including in particular novel monomaleimide-functionalized oxaliplatin and carboplatin derivatives, as well as their use as medicaments, particularly for the treatment or prevention of cancer.

Claim (Index 52):
The compound for use according to  claim 51  or the pharmaceutical composition for use according to  claim 51 , wherein said immunooncology therapeutic is selected from: an anti-CTLA-4 antibody which is preferably ipilimumab or tremelimumab; an anti-PD-1 antibody which is preferably nivolumab, pembrolizumab, pidilizumab, AMP-224, or APE02058; an anti-PD-L1 antibody which is preferably BMS-936559, MEDI4736, MPDL3280A, MDX-1105, or MEDI6469; an anti-TIM3 antibody; an anti-LAG3 antibody which is preferably BMS-986016, IMP701, or IMP731; an anti-OX4 antibody which is preferably MEDI0562; an anti-CSF1R antibody which is preferably IMC-CS4 or RG7155; an anti-IDO antibody; or an anti-CD40 antibody which is preferably CP-870,893 or Chi Lob 7/4.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 94.0
- Lexical Diversity: 1.2
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['10500516', '15093345', '14305643', '11691374', '15037941']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7638412102456756
- 35 USC 102 Novelty (BERT): 0.5146332338200096
- Combined Prediction Score: 0.738920412603109
- Mean Citation Score: 284.677548
- Max Citation Score: 286.78967
- Similarity Product: 192.528006304642

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test